• Spyre Therapeutics recently completed enrollment for the psoriatic arthritis and axial spondyloarthritis sub-studies in its SKYWAY Phase 2 trial of SPY072, while reiterating timelines for multiple rheumatic disease readouts and showcasing supportive preclinical anti-TL1A data at the 2026 European Congress of Rheumatology.
• Together with an expanded licensing field for SPY003 beyond inflammatory bowel disease, these developments highlight Spyre’s push to build a broader immunology franchise anchored in extended half-life biologics.
• We’ll now examine how the completion of SKYWAY enrollment and pending Phase 2 readouts could influence Spyre Therapeutics’ investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Spyre Therapeutics' Investment Narrative?

To own Spyre Therapeutics today, you really have to buy into the idea that an extended half-life immunology platform can justify a rich valuation despite zero revenue and increasing losses. The completion of SKYWAY enrollment and confirmation of the “6 in ’26” Phase 2 readout slate keep the near-term catalyst calendar intact, which helps explain the very large 1-year share price move and discount to consensus targets. The fresh TL1A preclinical data and the Paragon amendment expanding SPY003’s field both reinforce the longer-term pipeline story, though dosing restrictions push some optionality further out. On the risk side, the business still leans heavily on clinical outcomes, continued access to capital after large recent equity raises, and the market’s willingness to support premium price-to-book multiples.

However, one near-term risk investors should not overlook relates to future dilution and funding needs. Our comprehensive valuation report raises the possibility that Spyre Therapeutics is priced higher than what may be justified by its financials.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value views span roughly US$10 to US$96 per share, underscoring how differently people see Spyre’s upside. Set against dense 2026 trial readouts and ongoing cash burn, that spread underlines why it helps to compare several perspectives before forming your own view.

Explore 2 other fair value estimates on Spyre Therapeutics - why the stock might be worth as much as 26% more than the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Spyre Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Spyre Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Spyre Therapeutics' overall financial health at a glance.

No Opportunity In Spyre Therapeutics?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.